Get started
Author

Scott R. Berry

Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer
2017 · Safiya Karim, Kelly Brennan, et al. · JAMA Oncology · 98
PDF
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
2019 · Kelvin K. W. Chan, Helen Guo, et al. · Cancer Medicine · 88
PDF
Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs
2010 · Scott R. Berry, Chaim M. Bell, et al. · Journal of Clinical Oncology · 76
PDF
RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
2018 · Linda Trinh, Kelly P. Arbour-Nicitopoulos, et al. · International Journal of Behavioral Nutrition and Physical Activity · 67
PDF
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
2019 · Eric Xueyu Chen, Derek J. Jonker, et al. · Journal of Clinical Oncology · 40
Just Say Die
2007 · Scott R. Berry · Journal of Clinical Oncology · 36
The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study
2007 · Scott R Berry, Stacey Hubay, et al. · BMC Health Services Research · 35
PDF
The cancer specific advance directive
1998 · Scott R. Berry, Peter A. Singer · Cancer · 33
PDF
Ethical Challenges: Managing Oncology Drug Shortages
2013 · John Valgus, Eric A. Singer, et al. · Journal of Oncology Practice · 29
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
2012 · Peter A. Ubel, Scott R. Berry, et al. · Health Affairs · 26
High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate
2016 · Rehana Jamani, Esther K. Lee, et al. · European Journal of Clinical Pharmacology · 25
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
2019 · Eric Xueyu Chen, Derek J. Jonker, et al. · Journal of Clinical Oncology · 20
For Purposes of Research, Palliative Care Patients Should Not Be Considered a Vulnerable Population
2004 · S.R. Berry · Clinical Oncology · 20
Variation and Consternation: Access to Unfunded Cancer Drugs in Canada
2012 · Scott R. Berry, William K. Evans, et al. · Journal of Oncology Practice · 18
Overcoming Obstacles in Accessing Unfunded Oral Chemotherapy: Physician Experience and Challenges
2013 · Dolly Han, Martina Trinkaus, et al. · Journal of Oncology Practice · 8
Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care.
2013 · Scott R. Berry, Roxanne Cosby, et al. · Journal of Clinical Oncology · 7
Correction to: RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
2018 · Linda Trinh, Kelly P. Arbour-Nicitopoulos, et al. · International Journal of Behavioral Nutrition and Physical Activity · 6
PDF
Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).
2014 · Fred Saad, Eric Winquist, et al. · Journal of Clinical Oncology · 5
FDG PET/CT in pancreatic cancer staging and management: A retrospective study.
2017 · Ana Beatriz Kinupe Abrahao, Yee Ung, et al. · Journal of Clinical Oncology · 3
Cancer Care in South India: Perspectives from Visiting Canadian Oncologists
2016 · S. Karim, J.C. Del Paggio, et al. · Current Oncology · 3
PDF
Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer.
2015 · Esther K. Lee, Rehana Jamani, et al. · Journal of Clinical Oncology · 3
Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC).
2013 · Maria C. Riesco Martinez, Scott R. Berry, et al. · Journal of Clinical Oncology · 3
What price for a year of life? A survey of U.S. and Canadian oncologists
2009 · S. R. Berry, P. J. Neumann, et al. · Journal of Clinical Oncology · 3
Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer
2006 · Y. Ko, S. North, et al. · Journal of Clinical Oncology · 3
Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study.
2018 · Helen Guo, Jaclyn Marie Beca, et al. · Journal of Clinical Oncology · 2
Works count: 41
Citation count: 667
H-index: 14
I10-index: 14
Year
Topic
Type